Seward moves to new premises
Doubles manufacturing and storage facilities
The new building represents a significant investment by the company following the securing of a NatWest/RBS Manufacturing Fund. It will also ensure shorter lead times for the Stomacher sample preparation products for microbiological analyses and tissue processing, the company said.
The premises also house a purpose-built r&d laboratory for product development, application assessment and customer protocol development.
Further investment in web conferencing facilities will also allow training webinars and in-depth technical support to be offered to customers, wherever they are located.
The new premises support a much-needed increase in production capacity, driven by new applications and the opening of Seward Inc in Long Island, New York, US in 2009.
In the first half of 2010, sales of the Stomacher laboratory blenders grew by nearly 20%, compared with the same period in 2009. Sales of the Stomacher 80 biomaster range for small tissue processing increased by 53%, while the large volume Stomacher 3500 saw a 72% growth.
‘We are dedicated to maintaining excellence in our products, customer service and support for our rapidly growing global customer base, so the increased size and capacity of our new premises ensures we can guarantee this now and in the future,’ said Stuart Ray, technical director, Seward Ltd.
He added that the firm had also seen strong growth in the US and Asia/Pacific regions.
You may also like
Trending Articles
You may also like
Manufacturing
Domino demonstrates an integrated approach to next-generation coding at Interpack 2026
At Interpack 2026, Domino Printing Sciences (Domino) will focus on the key challenges manufacturers face as variable data printing enters a new era shaped by 2D codes, intelligent automation, sustainability, and growing traceability demands. Domino specialists will be available throughout the show to highlight integrated solutions designed to work together on the factory floor – developed in collaboration with key industry partners to help to reduce complexity, risk, and operational friction for manufacturers
Manufacturing
Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target
BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Manufacturing
Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair
Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model